A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

Date publication

octobre 2014

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25047747

Résumé

Evidence-based definitions of 'poor-prognosis' or 'aggressive' advanced breast cancer are lacking.

Mots clés

Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Agents, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, Breast Neoplasms, drug therapy, Decision Support Techniques, Drug Administration Schedule, Female, Humans, Middle Aged, Prognosis, Receptor, ErbB-2, metabolism, Risk Assessment, Risk Factors, Survival Rate, Taxoids, administration & dosage

Référence

Breast. 2014 Oct;23(5):656-62